Skip to search formSkip to main contentSkip to account menu

vicriviroc

A piperazine-based CCR5 receptor antagonist with activity against human immunodeficiency virus. Vicriviroc is designed to bind to CCR5 and inhibit… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

PiperazinesPyrimidines

Narrower (1)

Sch-417690
Vicriviroc Maleate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Efficacy of new antiretroviral drugs in treatment‐experienced HIV‐infected patients: a systematic review and meta‐analysis of recent randomized controlled trials
We performed a systematic review and meta‐analysis of randomized controlled trials (RCTs) to assess the overall efficacy of new… 
2011
2011
Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands.
The inherent instability of heptahelical G protein-coupled receptors (GPCRs) during purification and reconstitution is a primary… 
2010
2010
Short-Term Administration of the CCR5 Antagonist Vicriviroc to Patients With HIV and HCV Coinfection Is Safe and Tolerable
Objective:CCR5 antagonists block HIV cell entry through competitive binding to the CCR5 receptor present on the surface of CD4… 
Review
2010
Review
2010
Effect of Vicriviroc on the QT/Corrected QT Interval and Central Nervous System in Healthy Subjects
ABSTRACT Vicriviroc is a CCR5 antagonist in clinical development for the treatment of HIV-1. Two phase I studies were conducted… 
Highly Cited
2009
Highly Cited
2009
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.
The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study… 
Review
2009
Review
2009
HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
The recent availability of new antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection has… 
Review
2009
Review
2009
Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.
Highly active antiretroviral therapy has revolutionized the care of patients with HIV infection, but treatment is often… 
Review
2009
Review
2009
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C–C motif) receptor 5 antagonists]
Purpose of reviewTo provide an update on viral entry inhibitors focusing on recently published clinical trials, the routine… 
Highly Cited
2007
Highly Cited
2007
Response normalized liquid chromatography nanospray ionization mass spectrometry
Review
2007
Review
2007
CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
In the context of emerging resistance to antiretroviral agents in HIV medicine, the development of new drugs classes with a novel… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)